Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Effect of metformin on plasma metabolite profile in the Copenhagen Insulin and Metformin Therapy (CIMT) trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Acupuncture for chronic hepatitis B

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exercise-Based Rehabilitation for Heart Failure: Cochrane Systematic Review, Meta-Analysis, and Trial Sequential Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • N Safai
  • T Suvitaival
  • Ali A
  • P Spégel
  • M Al-Majdoub
  • B Carstensen
  • H Vestergaard
  • M Ridderstråle
  • CIMT Trial Group
  • Louise Lundby-Christensen (Medlem af forfattergruppering)
  • Lise Tarnow (Medlem af forfattergruppering)
  • Birger Thorsteinsson (Medlem af forfattergruppering)
  • Christian Gluud (Medlem af forfattergruppering)
  • Michael Einar Røder
Vis graf over relationer

AIM: Metformin is the first-line treatment for Type 2 diabetes. However, not all people benefit from this drug. Our aim was to investigate the effects of metformin on the plasma metabolome and whether the pretreatment metabolite profile can predict HbA1c outcome.

METHODS: Post hoc analysis of the Copenhagen Insulin and Metformin Therapy (CMIT) trial, a multicentre study from May 2008 to December 2012, was carried out. We used a non-target method to analyse 87 plasma metabolites in participants with Type 2 diabetes (n = 370) who were randomized in a 1 : 1 ratio to 18 months of metformin or placebo treatment. Metabolites were measured by liquid chromatography-mass spectrometry at baseline and at 18-month follow-up and the data were analysed using a linear mixed-effect model.

RESULTS: At baseline, participants who were on metformin before the trial (n = 312) had higher levels of leucine/isoleucine and five lysophosphatidylethanolamines (LPEs), and lower levels of carnitine and valine compared with metformin-naïve participants (n = 58). At follow-up, participants randomized to metformin (n = 188) had elevated levels of leucine/isoleucine and reduced carnitine, tyrosine and valine compared with placebo (n = 182). At baseline, participants on metformin treatment with the highest levels of carnitine C10:1 and leucine/isoleucine had the lowest HbA1c (P-interaction = 0.02 and 0.03, respectively). This association was not significant with HbA1c at follow-up.

CONCLUSIONS: Metformin treatment is associated with decreased levels of valine, tyrosine and carnitine, and increased levels of leucine/isoleucine. None of the identified metabolites can predict the HbA1c -lowering effect of metformin. Further studies of the association between metformin, carnitine and leucine/isoleucine are warranted. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftDiabetic Medicine Online
Vol/bind35
Udgave nummer7
Sider (fra-til)944-953
Antal sider9
ISSN1464-5491
DOI
StatusUdgivet - jul. 2018

ID: 53618303